Allan Peck, MD
Gastroenterology · Cincinnati, OHNPI 1588663561
Payments from drug & device makers
Across 1,155 payments — averaging $338.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$241K
- Phathom Pharmaceuticals, Inc.$93K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$42K
- Johnson & Johnson$3K
- Ironwood Pharmaceuticals, Inc$3K
- Amgen$2K
- plus $7K from 30 others
What the payments were for
- Consulting fees$3,7401%
- Speaking & faculty fees$339,53887%
- Travel & lodging$19,1075%
- Food & beverage$28,5067%
- Education$5510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 576 | $240,818 |
| Phathom Pharmaceuticals, Inc. | 142 | $93,294 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 87 | $42,315 |
| Johnson & Johnson | 59 | $3,077 |
| Ironwood Pharmaceuticals, Inc | 27 | $2,734 |
| Amgen | 3 | $2,205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 70 | $1,429 |
| Janssen Scientific Affairs, LLC | 8 | $996 |
| Regeneron Healthcare Solutions, Inc. | 49 | $785 |
| Bristol Myers Squibb | 25 | $662 |
| Madrigal Pharmaceuticals | 4 | $403 |
| E.r. Squibb & Sons, L.L.C. | 3 | $358 |
| Boston Scientific | 3 | $285 |
| Regeneron | 2 | $281 |
| Redhill Biopharma Inc. | 5 | $238 |
| QOL Medical, LLC | 12 | $235 |
| Nestle Healthcare Nutrition Inc. | 25 | $208 |
| Sanofi | 7 | $207 |
| Aimmune Therapeutics, Inc. | 7 | $178 |
| Gilead | 8 | $119 |
| Lilly USA, LLC | 5 | $99 |
| Pfizer | 5 | $81 |
| Ardelyx, Inc. | 1 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $67 |
| Organon | 4 | $56 |
| Celltrion USA Inc. | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Vivus LLC | 1 | $20 |
| Mylan Institutional Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Romark Laboratories, LC | 2 | $15 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$391,442 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 25 | $634,810 |
| Humira(Cf) PenAdalimumab | 21 | $146,169 |
| CreonLipase/Protease/Amylase | 17 | $97,561 |
| LinzessLinaclotide | 69 | $80,731 |
| Humira PenAdalimumab | 11 | $78,433 |
| ZenpepLipase/Protease/Amylase | 15 | $46,517 |
| VoqueznaVonoprazan Fumarate | 22 | $24,329 |
| Mesalamine | 25 | $23,398 |
| Mesalamine ErMesalamine | 19 | $7,290 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 107 | $6,738 |
| Pantoprazole Sodium | 313 | $4,129 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 22 | $3,573 |
| Budesonide DrBudesonide | 37 | $2,914 |
| Lubiprostone | 23 | $2,833 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 15 | $2,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $3,077 | $634,81025 claims |
| AbbVieCreon, Linzess | $240,818 | $178,29386 claims |
| Aimmune Therapeutics, Inc.Zenpep | $178 | $46,51715 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $93,294 | $24,32922 claims |
| Braintree Laboratories, Inc.Sutab | $14 | $3,57322 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $42,315 | $2,05915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Cincinnati
- Anita AfzaliCincinnati$2.4M
- Pradeep BekalCincinnati$1.4M
- Loren BrookCincinnati$1.2M
- Ravi RavinuthalaCincinnati$843K
- Kara de FeliceCincinnati$527K
- Vidhya KunnathurCincinnati$456K
- Bruce YacyshynCincinnati$411K
- Luis LaraCincinnati$314K
- Robert IsfortCincinnati$280K
- Michael KreinesCincinnati$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.